REILLY FINANCIAL ADVISORS, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
REILLY FINANCIAL ADVISORS, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2021$5,0000.0%2,0000.0%0.00%
Q3 2021$5,000
-16.7%
2,0000.0%0.00%
Q2 2021$6,000
+20.0%
2,0000.0%0.00%
Q1 2021$5,000
+25.0%
2,0000.0%0.00%
Q4 2020$4,000
+100.0%
2,0000.0%0.00%
Q3 2020$2,0000.0%2,0000.0%0.00%
Q2 2020$2,0000.0%2,0000.0%0.00%
Q1 2020$2,0000.0%2,0000.0%0.00%
Q4 2019$2,0000.0%2,0000.0%0.00%
Q3 2019$2,0002,0000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders